Lucatumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD40 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
903512-50-5  |
| ChemSpider | none |
| UNII |
P0EP9VFC4R  |
| KEGG |
D08942 |
| Chemical and physical data | |
| Molar mass | 146 kg/mol |
| (what is this?) (verify) | |
Lucatumumab is a human monoclonal antibody[1] being investigated for the treatment of various types of cancer like multiple myeloma,[2] non-Hodgkin's or Hodgkin's lymphoma.[3]
This drug was developed by Novartis Pharmaceuticals Corp.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ↑ Clinical trial number NCT00231166 at ClinicalTrials.gov
- ↑ Clinical trial number NCT00670592 at ClinicalTrials.gov
This article is issued from Wikipedia - version of the 9/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.